In a patient with history of stage III NSCLC who progresses to IV on maintenance durvalumab who is then found to have actionable mutation (EGFR, ALK), do you move directly on to targeted therapies even though there might be higher risk of toxicity including pneumonitis when TKI follows checkpoint inhibitor?